Development of gelatin nanoparticles with biotinylated EGF conjugation for lung cancer targeting

Since lung cancer is the most malignant cancer today, a specific drug-delivery system has been developed for superior outcome. In this study, gelatin nanoparticles (GPs) employed as native carriers were grafted with NeutrAvidinFITC on the particleʹs surface (GP–Av). Next, the biotinylated epithelial growth factor (EGF) molecules were conjugated with NeutrAvidinFITC, forming a core-shell-like structure (GP–Av–bEGF) to achieve the enhancement of targeting efficiency. These nanoparticles were applied as an EGF receptor (EGFR)-seeking agent to detect lung adenocarcinoma. The results showed that the modification process had no significant influence on particle size (220 nm) and zeta potential (−9.3 mV). By the in vitro cell culture test, GP–Av–bEGF resulted in higher entrance efficiency on adenocarcinoma cells (A549) than that on normal lung cells (HFL1) because A549 possessed greater amounts of EGFR. We also found that uptake of GP–Av–bEGF by A549 cells was time and dose dependent. Confocal microscopy confirmed the cellular internalization of GP–Av–bEGF, and more fluorescent spots of GP–Av–bEGF nanoparticles were obviously observed as well as lysosomal entrapment in A549. Finally, the delivery was demonstrated by in vivo aerosol administration to cancerous lung of the SCID mice model, and specific accumulation in cancerous lung was confirmed by image quantification. The targeting ability of GP–Av–bEGF was proved in vitro and in vivo, which holds promise for further anti-cancer drug applications.